The present disclosure relates to a novel spherical agglomeration method for proteins, and protein particles made by the spherical agglomeration method. By using continuous oscillatory baffled crystallizer, the method of the present disclosure is capable of maintain the biologically activities and providing protein particles with an average particle size between 1-500 μm.

The present invention provides novel blockers of the potassium channel Kv1.3, polynucleotides encoding them, and methods of making and using them.

Provided are processes and materials for solving biological or structural information about proteins or other organic molecules. The processes capitalize on a rigid multimeric nanocage formed from self-assembling substructure proteins. The processes and materials allow for recognition and tight, optionally covalent, bonding of any protein molecule with a tag complementary to a capture sequence on the nanocage. The processes and materials may be used to obtain biological or structural information by cryo-electron microscopy and overcome prior limitations of target protein size or salt concentration.

Provided are processes and materials for solving biological or structural information about proteins or other organic molecules. The processes capitalize on a rigid multimeric nanocage formed from self-assembling substructure proteins. The processes and materials allow for recognition and tight, optionally covalent, bonding of any protein molecule with a tag complementary to a capture sequence on the nanocage. The processes and materials may be used to obtain biological or structural information by cryo-electron microscopy and overcome prior limitations of target protein size or salt concentration.

Compositions are provided that comprise peptide receptive MHC class I complexes (peptide receptive MHC-I complexes) that are formed after treatment with a catalytic amount of chaperone (i.e. a ratio of chaperone to MHC-I of less than 1:1). In particular, these peptide receptive MHC class I complexes can be used to form peptide-MHC class I (pMHC-I) multimers that can be used in high throughput applications such as detection of antigen specific T cells and characterization of T cell profiles in subjects.

Compositions are provided that comprise peptide receptive MHC class I complexes (peptide receptive MHC-I complexes) that are formed after treatment with a catalytic amount of chaperone (i.e. a ratio of chaperone to MHC-I of less than 1:1). In particular, these peptide receptive MHC class I complexes can be used to form peptide-MHC class I (pMHC-I) multimers that can be used in high throughput applications such as detection of antigen specific T cells and characterization of T cell profiles in subjects.

The invention relates to multimeric fusion proteins which bind to human Fc receptors. The invention also relates to therapeutic compositions comprising the proteins, and their use in the treatment of immune disorders.

Disclosed herein are novel processes for preparing IL-2 conjugates with one or more water-soluble polymers. In one embodiment, the IL-2 conjugate comprises five poly(ethylene glycol) polymers each of which is covalently attached to the IL-2 moiety via a releasable linkage to an amino group of the IL-2 moiety.

Disclosed herein are novel processes for preparing IL-2 conjugates with one or more water-soluble polymers. In one embodiment, the IL-2 conjugate comprises five poly(ethylene glycol) polymers each of which is covalently attached to the IL-2 moiety via a releasable linkage to an amino group of the IL-2 moiety.

The present disclosure provides compositions and methods for selectively killing senescent cells, wherein the selective killing of senescent cells delays aging and treats age-related disorders.